Evidence map›Paper›PMID 25784996›Full record

ArticleInternational journal of clinical and experimental medicine2015

ABCB1 (rs1128503) polymorphism and response to chemotherapy in patients with malignant tumors-evidences from a meta-analysis.

Zifei Zhou, Quanchi Chen, Dongqing Zuo, Hongsheng Wang, Yingqi Hua, Zhengdong Cai

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in International journal of clinical and experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 2 pooled it
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Pharmacogenomics and Morphine.Journal of clinical pharmacology · 2021
    Review
  6. Article
  7. Association betweenOncology letters · 2020
    Article
  8. Article
  9. Review
  10. Association between XRCC3 Thr241Met polymorphism and risk of osteosarcoma in a Chinese population.International journal of clinical and experimental pathology · 2015
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Zifei ZhouDepartment of Orthopedics, Shanghai Tenth People's Hospital, Tongji University, School of Medicine 301 Middle Yanchang Road, Shanghai 200072, China.
Quanchi ChenDepartment of Orthopedics, Shanghai Tenth People's Hospital, Tongji University, School of Medicine 301 Middle Yanchang Road, Shanghai 200072, China.
Dongqing ZuoDepartment of Orthopedics, Shanghai Tenth People's Hospital, Tongji University, School of Medicine 301 Middle Yanchang Road, Shanghai 200072, China.
Hongsheng WangDepartment of Orthopedics, Shanghai Tenth People's Hospital, Tongji University, School of Medicine 301 Middle Yanchang Road, Shanghai 200072, China.
Yingqi HuaDepartment of Orthopedics, Shanghai Tenth People's Hospital, Tongji University, School of Medicine 301 Middle Yanchang Road, Shanghai 200072, China.
Zhengdong CaiDepartment of Orthopedics, Shanghai Tenth People's Hospital, Tongji University, School of Medicine 301 Middle Yanchang Road, Shanghai 200072, China.
Shanghai Tenth People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Numerous papers have reported ABCB1 polymorphisms are associated with the response to chemotherapy of cancers. The inconclusive results call for a comprehensive analysis, for the sample size of the published studies is comparatively small. Therefore, a comprehensive meta-analysis was performed on the basis of the published studies for an accurate estimation of such association. Altogether 8 comparative studies including 2463 cancer patients were involved in our meta-analyses. ABCB1 C1236T (rs1128503) polymorphism was shown to be associated with tumor response to chemotherapy in cancer patients under the dominant model (OR=1.72, 95% CI=1.09-2.73, P=0.177, I(2)=36.60%) and additive model (OR=1.99, 95% CI=1.39-2.85, P=0.222, I(2)=25.90%). A subgroup meta-analysis indicated a significant association under dominant model between ABCB1 C1236T (rs1128503) polymorphism and breast cancer in the Asians (OR=2.15, 95% CI=1.22-3.77, P=0.210, I(2)=33.70%). These results suggest that ABCB1 C1236T (rs1128503) might contribute to the tumor response to chemotherapy in cancers from the Asians, especially in the osteosarcoma and breast cancer.

Indexed as

cancerchemotherapyPolymorphismtumor response

Identifiers

PMID25784996
PMCPMC4358451
OpenAlexW94622063

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.